Date: May 28, 2022

Your Name: Artmis Youssefnia

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | |
|------|---|--------------------------------|------------|---|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. Nana | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | meetings and, or traver | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | - |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | XNone | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Plea | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | lono | | | |
| | lone. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022 Your Name: Alicia Pierre

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | |
|-----|---|--------------------------------|------------|--|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. None | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | X None | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| 10 | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Ple | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | | | | |
| 1 | None. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022

Your Name: Jeffrey M. Hoder

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | |
|-----|---|--------------------------------|------------|--|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. None | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | X None | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| 10 | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Ple | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | | | | |
| 1 | None. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022

Your Name: Michelle MacDonald

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | |
|------|---|--------------------------------|------------|---|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. Nana | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | meetings and, or traver | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | - |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | XNone | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Plea | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | lono | | | |
| | lone. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022

Your Name: Monica J.B. Shaffer

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | |
|------|---|--------------------------------|------------|---|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. Nana | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | meetings and, or traver | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | - |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | XNone | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Plea | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | lono | | | |
| | lone. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022

Your Name: Jessica Friedman

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | |
|-----|---|--------------------------------|------------|--|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| | educational events | V. None | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | XNone | | |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | X None | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy | | | |
| | group, paid or unpaid | | | |
| 11 | Stock or stock options | XNone | | |
| | | | | |
| 10 | | | | |
| 12 | Receipt of equipment, | X_None | | |
| | materials, drugs, medical writing, gifts or other | | | |
| | services | | | |
| | | | | |
| 13 | Other financial or non- | XNone | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Ple | ase summarize the above co | nflict of interest in the foll | owing box: | |
| | | | | |
| 1 | None. | | | |
| | | | | |
| | | | | |

Date: May 28, 2022

Your Name: Philip S. Mehler

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|---|---------|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | V. None | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | X None | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| 10 | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical writing, gifts or other | | | | |
| | services | | | | |
| | | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |
| 1 | None. | | | | |
| | | | | | |
| | | | | | |

Date: May 28, 2022

Your Name: Amanda Bontempo

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|---|---------|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | V. None | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | X None | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| 10 | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical writing, gifts or other | | | | |
| | services | | | | |
| | | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |
| 1 | None. | | | | |
| | | | | | |
| | | | | | |

Date: May 28, 2022

Your Name: Francisco C.N. da Silva

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A Narrative

Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | | |
|------|---|---------|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | V. Nana | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | | | | |
| | meetings and, or traver | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical writing, gifts or other | | | | |
| | services | | | | |
| | | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | |
| | lono | | | | |
| | lone. | | | | |
| | | | | | |
| | | | | | |

Date: May 28, 2022

Your Name: Edward D. Chan

Manuscript Title: Ancillary Treatment of Patients with Lung Disease due to Non-tuberculous Mycobacteria: A

Narrative Review

Manuscript number (if known): JTD-22-410-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|---|---------|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | V. None | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | X None | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| 10 | | | | | |
| 12 | Receipt of equipment, | X_None | | | |
| | materials, drugs, medical writing, gifts or other | | | | |
| | services | | | | |
| | | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |
| 1 | None. | | | | |
| | | | | | |
| | | | | | |